beta-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer Disease Dream or Reality?

Author: Talaga P.

Source: Mini Reviews in Medicinal Chemistry, Volume 1, Number 2, July 2001 , pp. 175-186(12)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Amyloid (A beta) deposition remains a hallmark in the pathology of Alzheimer disease (AD). Important drug discovery efforts dedicated to the inhibition of the polymerization process leading to amyloid neurotoxicity are pursued by academic groups and the pharmaceutical industry as a potential preventive treatment for AD. The aim of this review is to up-date current knowledge on the amyloid aggregation process and the various available peptidic and non-peptidic A beta aggregation inhibitors.

Keywords: Aggregation Inhibitors; Alzheimers Disease; Anti-inflammatory agents; Antioxidants; Neurotrophic; Ab Aggregation Inhibition; AMYLOID AGGREGATION INHIBITORS; Thyrotrophin releasing hormone (TRH); Melatonin; Hexadecyl-N-methylpiperidinium (HMP) bromide

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389557013407098

Publication date: 2001-07-01

More about this publication?

The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.